HUAKANG(SH:605077) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2026-01-09 23:02Core Viewpoint - Zhejiang Huakang Pharmaceutical Co., Ltd. announced the early repurchase of shares involved in stock pledge repurchase transactions by certain controlling shareholders and their concerted actors, indicating a significant reduction in pledged shares and potential positive implications for shareholder confidence and company stability [1][6]. Group 1: Stock Pledge Repurchase - The controlling shareholders, Cheng Xinping, Xu Xiaorong, and Yu Jianming, repurchased a total of 25,500,000 shares, which accounts for 8.41% of the company's total share capital [1]. - The repurchased shares do not have any subsequent pledge plans, and the company will fulfill its information disclosure obligations if there are any future pledges [1]. Group 2: Shareholder Pledge Situation - As of the announcement date, the cumulative pledged shares by controlling shareholders and their concerted actions are detailed, indicating ongoing monitoring of shareholder equity [2]. Group 3: Convertible Bond Reduction - From January 1 to January 9, 2026, the actual controllers reduced their holdings of convertible bonds by 1,663,720 units, representing 12.77% of the total issued convertible bonds [3][4]. - This reduction led to a change in the combined equity ratio of the actual controllers from 27.40% to 26.30%, a decrease of 1.10% [3][4]. - The reduction in convertible bonds does not trigger a mandatory tender offer and will not change the actual control of the company [3][5].